Genomtec secured €2.6 million equity financing to support commercialization of its molecular diagnostics platforms, including a portable microfluidic system (Genomtec ID) and OncoSNAAT liquid biopsy technology for precision oncology. The company plans to use part of the round to develop AI-assisted primer design for loop-mediated amplification (LAMP) assays, targeting lower time and cost for test development, and to drive strategic partnerships in molecular testing workflows.